Abstract
Introduction: The purpose of this retrospective study was to determine the relationship between pretherapy hemoglobin levels and progression-free survival among women with uterine cervix cancer undergoing concurrent weekly cisplatin and radiotherapy followed by brachytherapy. Methods: Patients with advanced-stage II-IVA uterine cervix cancer were grouped by hemoglobin level (Hgb ≥ 12.0, 11.9-10.0, or < 10.0 g/dL). Endpoints were progression-free survival, overall survival, and local control. Results: Between 01/2001 and 07/2022, 168 patients contributed demographic, tumor, pretherapy hemoglobin, and outcome data with a median follow-up of 31 months. Progression-free survival at three years was 73% (95% confidence interval: 58%-84%), 71% (95% confidence interval: 56%-82%), and 62% (95% confidence interval: 44%-75%) for the Hgb ≥ 12.0, 11.9-10.0, or < 10.0 g/dL groups, respectfully (P < 0.001). In addition, pretherapy hemoglobin levels were significant with treatment outcome when included in a multivariate analysis of prognostic variables. Discussion: In conclusion, the difference in pretherapy hemoglobin level was prognostic of progression-free survival.
Original language | English |
---|---|
Article number | 1132135 |
Journal | Frontiers in Oncology |
Volume | 13 |
DOIs | |
State | Published - 2023 |
Bibliographical note
Funding Information:This work was supported by NCI grant P30 CA177558 which supports the Biostatistics and Bioinformatics and the Cancer Research Informatics Shared Resource Facilities of the University of Kentucky Markey Cancer Center.
Publisher Copyright:
Copyright © 2023 Kunos, Fabian, Fredericks, Baldwin, Dietrich, Miller and Ueland.
Keywords
- Appalachia
- cervical cancer
- hemoglobin
- survival
- uterine cervix
ASJC Scopus subject areas
- Oncology
- Cancer Research